MiR-375 in CAFs-Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer-associated fibroblasts (CAFs) are key players in the tumor microenvironment, influencing cancer progression through cell-to-cell communication.
• Extracellular vesicles (EVs) mediate intercellular communication, carrying molecular cargo between cells.
• Hepatocellular carcinoma (HCC) is a major global health concern with complex underlying mechanisms of progression.

Purpose of the Study:

• To investigate the role of CAFs-derived EVs in hepatocellular carcinoma (HCC) angiogenesis.
• To identify the specific molecular cargo delivered by CAFs-derived EVs and its mechanism of action.
• To evaluate the potential of miR-375 within EVs as a biomarker for HCC.

Main Methods:

• Isolation and characterization of extracellular vesicles (EVs) from cancer-associated fibroblasts (CAFs).
• Delivery of CAFs-derived EVs containing miR-375 to endothelial cells (ECs).
• Analysis of Ras GTPase Activating Protein 1 (RASA1) regulation by miR-375.
• Quantification of miR-375 levels in plasma EVs from HCC patients with varying disease stages.

Main Results:

• CAFs-derived EVs deliver miR-375 to endothelial cells (ECs), promoting tumor angiogenesis in HCC.
• miR-375 regulates angiogenesis by targeting Ras GTPase Activating Protein 1 (RASA1).
• Higher levels of miR-375 in plasma EVs correlate with advanced HCC disease stages and are preferentially found in CAFs-derived EVs.

Conclusions:

• Tumor suppressor miR-375, selectively packaged into CAF-derived EVs, promotes angiogenesis in HCC progression.
• Genetically modified CAF-derived EVs present a potential therapeutic strategy for HCC.
• miR-375 in plasma EVs shows promise as a predictive and prognostic biomarker for HCC patients.